PCSK9 Inhibitors: What You Need to Know

Updated July 2026

PCSK9 inhibitors are a newer class of cholesterol-lowering drugs that can lower LDL far more than statins can, and they have become a mainstream option for people who need extra help getting their numbers down. The field is also moving fast: prices have fallen sharply, and the first oral version is close to approval. Here is what these drugs are, how well they work, what they cost, and where they fit alongside the basics.

What are PCSK9 inhibitors and how do they work?

They work by helping your liver pull more LDL out of your blood. LDL receptors are the cleanup crew that removes LDL, the "bad" cholesterol, from your bloodstream, and the more receptors you have, the lower your LDL. PCSK9 is a naturally occurring protein that destroys those receptors, which drives LDL up. Researchers first got interested when they found that people born with naturally low PCSK9 levels had very low LDL and lots of active receptors. Block or reduce PCSK9, and more receptors survive to clear LDL from the blood.

There are three approved options, working in two ways. Repatha (evolocumab) and Praluent (alirocumab) are antibodies that latch onto the PCSK9 protein and mark it for removal. Leqvio (inclisiran) works one step earlier, using a technology called siRNA to keep your body from producing PCSK9 in the first place, conceptually a little like how the mRNA vaccines instruct cells.

How much do they lower cholesterol, and how are they taken?

They lower LDL dramatically, more than even the highest doses of the strongest statins. The antibodies drop LDL by roughly 60%, and Leqvio by about 50%. Repatha and Praluent are self-injected at home every two weeks, while Leqvio is given as an injection in your doctor's office just twice a year after two starter doses. Large trials have shown that this lowering translates into fewer heart attacks and strokes, and the drugs have been generally well tolerated, with side effects mostly limited to injection-site reactions or cold-like symptoms.

Is there a pill version of PCSK9 inhibitors?

Almost. An oral, once-daily PCSK9 pill called enlicitide is in late-stage testing and is expected to reach the market in late 2026. In its pivotal trial, published in the New England Journal of Medicine, it lowered LDL by roughly 56 to 60%, matching the injectable versions, in a simple daily tablet. That matters because the needle is a real barrier for many people, so an equally effective pill could bring this level of cholesterol lowering to far more patients.

What do PCSK9 inhibitors cost in 2026?

Much less than they used to. When these drugs launched around 2015, they cost roughly $14,000 a year, which put them out of reach for most people and made insurers reluctant to cover them. Since then, list prices have fallen by about 60%, to roughly $6,000 a year, and access has improved in several ways. Medicare now caps a person's yearly out-of-pocket drug costs at about $2,100, commercial copay cards can bring the cost down to a few dollars a month, and one manufacturer now sells its version directly to patients for cash at about $239 a month. Insurers still typically require you to try a statin first and to get prior authorization, but the affordability picture is far better than it was a decade ago.

So what does this mean for you?

These drugs are a real advance, and they are becoming cheaper and easier to take, but a few things are worth keeping in perspective. They are lifelong medications, not a short course you finish and forget, so long-term safety matters, and our understanding of any newer drug keeps evolving with time. It is worth remembering that it took about 25 years of statin use before we recognized that statins modestly raise the risk of developing diabetes. That is not a reason to avoid treatment when you need it, just a reason to stay thoughtful.

The bigger point is that PCSK9 inhibitors, like statins, treat a single number. They do not address why that number is high in the first place. High cholesterol, high blood pressure, high blood sugar, and excess weight are all tied closely to what we eat, and no injection or pill changes the value of feeding your body well.

That is the entire idea behind Step One Foods. We put meaningful doses of the fiber, phytosterols, and omega-3s shown to lower cholesterol into two simple servings a day, and we proved it works in a randomized controlled trial conducted with Mayo Clinic and the University of Manitoba. For many people, food is enough to reach their goal. For others, it lowers the dose or the number of medications they need. And the frontier is moving quickly, all the way to one-time gene therapies that may someday lower LDL permanently. But whatever the tools, the foundation does not change. The most powerful, least expensive, and safest place to start is still your plate.

If you're new to this site and found this useful, I write one of these evidence-based articles every week. You can get them in your inbox by joining my email list at the bottom of this page. No spam, no requirement to buy anything, just practical knowledge.